MX2017015837A - Procesos e intermediarios para la preparacion de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-piraz ol-1-il]azetidin-3-il}acetonitrilo. - Google Patents

Procesos e intermediarios para la preparacion de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-piraz ol-1-il]azetidin-3-il}acetonitrilo.

Info

Publication number
MX2017015837A
MX2017015837A MX2017015837A MX2017015837A MX2017015837A MX 2017015837 A MX2017015837 A MX 2017015837A MX 2017015837 A MX2017015837 A MX 2017015837A MX 2017015837 A MX2017015837 A MX 2017015837A MX 2017015837 A MX2017015837 A MX 2017015837A
Authority
MX
Mexico
Prior art keywords
razol
azetidin
ethylsulfonyl
pyrrolo
pyrimidin
Prior art date
Application number
MX2017015837A
Other languages
English (en)
Inventor
Edward Kobierski Michael
E Kopach Michael
R Martinelli Joseph
Lee Varie David
Michael Wilson Thomas
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56204068&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017015837(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2017015837A publication Critical patent/MX2017015837A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7H-pirrolo[2,3-d]pirimid in-4-il)-1H-pirazol-1-iI]azetidin-3-il}acetonitrilo: (ver Fórmula).
MX2017015837A 2015-06-19 2016-06-16 Procesos e intermediarios para la preparacion de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-piraz ol-1-il]azetidin-3-il}acetonitrilo. MX2017015837A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562182040P 2015-06-19 2015-06-19
PCT/US2016/037832 WO2016205487A1 (en) 2015-06-19 2016-06-16 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF {1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]AZETIDIN-3-YL}ACETONITRILE

Publications (1)

Publication Number Publication Date
MX2017015837A true MX2017015837A (es) 2018-04-10

Family

ID=56204068

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015837A MX2017015837A (es) 2015-06-19 2016-06-16 Procesos e intermediarios para la preparacion de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-piraz ol-1-il]azetidin-3-il}acetonitrilo.

Country Status (26)

Country Link
US (2) US20180134713A1 (es)
EP (1) EP3310781A1 (es)
JP (1) JP2018519280A (es)
KR (1) KR20180008637A (es)
CN (1) CN107660206A (es)
AR (1) AR104918A1 (es)
AU (1) AU2016280815A1 (es)
BR (1) BR112017024613A2 (es)
CA (1) CA2984627A1 (es)
CL (1) CL2017003112A1 (es)
CO (1) CO2017013226A2 (es)
CR (1) CR20170533A (es)
DO (1) DOP2017000300A (es)
EA (1) EA201792308A1 (es)
EC (1) ECSP17083426A (es)
HK (1) HK1248699A1 (es)
IL (1) IL255386A0 (es)
MA (1) MA45901A (es)
MX (1) MX2017015837A (es)
NZ (1) NZ736999A (es)
PE (1) PE20180504A1 (es)
PH (1) PH12017502360A1 (es)
SV (1) SV2017005586A (es)
TN (1) TN2017000530A1 (es)
TW (1) TWI622591B (es)
WO (1) WO2016205487A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108341818A (zh) * 2017-01-21 2018-07-31 南京华威医药科技开发有限公司 巴瑞克替尼及其磷酸盐的新晶型及其制备方法
AU2018209579B2 (en) 2017-01-23 2020-12-24 Shanghai Longwood Biopharmaceuticals Co., Ltd. JAK kinase inhibitor and preparation method and use thereof
CN106946917B (zh) * 2017-03-20 2019-06-11 杭州科巢生物科技有限公司 一种jak抑制剂巴瑞替尼及其中间体的新合成方法
CN107739328B (zh) * 2017-11-22 2020-03-20 海化生命(厦门)科技有限公司 用于合成巴瑞替尼的关键中间体1的制备方法
CN108129482A (zh) * 2017-12-13 2018-06-08 江苏中邦制药有限公司 一种巴瑞替尼的制备方法
US10766900B2 (en) 2017-12-29 2020-09-08 Formosa Laboratories, Inc. Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof
WO2020072870A1 (en) 2018-10-05 2020-04-09 Johnson Matthey Public Limited Company Co-crystal forms of baricitinib
TW202033198A (zh) 2018-10-17 2020-09-16 美商美國禮來大藥廠 以巴瑞克替尼(baricitinib)治療原發性膽汁性膽管炎及原發性硬化性膽管炎
AR118750A1 (es) 2019-04-24 2021-10-27 Elanco Us Inc UN PROCESO PARA PREPARAR UNA FORMA CRISTALINA DE 2-(3-(4-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL)-1-(CICLOPROPILSULFONILO)AZETIDIN-3-IL)ACETONITRILO QUE POSEE ACTIVIDAD INHIBIDORA DE JAK
IL310420A (en) 2021-07-30 2024-03-01 Lilly Co Eli Treatment of hand eczema with BARICITINIB

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821374A (en) * 1995-11-21 1998-10-13 Hoffmann-La Roche Inc. Process for the oxidation of alcohols
TWI444382B (zh) * 2008-03-11 2014-07-11 Incyte Corp 作為ｊａｋ抑制劑之氮雜環丁烷及環丁烷衍生物
WO2011130146A1 (en) * 2010-04-14 2011-10-20 Array Biopharma Inc. 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
CN102557901B (zh) * 2010-12-15 2014-06-11 上海医药工业研究院 6-氯己醛的制备方法
HUE057262T2 (hu) * 2013-03-06 2022-04-28 Incyte Holdings Corp Eljárás és köztitermékek JAK inhibitor elõállítására
CN105541891B (zh) * 2016-02-04 2017-11-28 东南大学 巴瑞替尼的中间体及其制备方法及由该中间体制备巴瑞替尼的方法

Also Published As

Publication number Publication date
CL2017003112A1 (es) 2018-06-01
TN2017000530A1 (en) 2019-04-12
TW201712015A (zh) 2017-04-01
SV2017005586A (es) 2018-04-24
BR112017024613A2 (pt) 2018-07-31
DOP2017000300A (es) 2018-01-31
CN107660206A (zh) 2018-02-02
ECSP17083426A (es) 2018-02-28
PE20180504A1 (es) 2018-03-09
EA201792308A1 (ru) 2018-05-31
KR20180008637A (ko) 2018-01-24
JP2018519280A (ja) 2018-07-19
MA45901A (fr) 2019-06-19
NZ736999A (en) 2019-05-31
PH12017502360A1 (en) 2018-06-25
CA2984627A1 (en) 2016-12-22
CR20170533A (es) 2018-01-25
AR104918A1 (es) 2017-08-23
CO2017013226A2 (es) 2018-03-28
AU2016280815A1 (en) 2017-11-23
EP3310781A1 (en) 2018-04-25
HK1248699A1 (zh) 2018-10-19
US20180134713A1 (en) 2018-05-17
US20190062337A1 (en) 2019-02-28
WO2016205487A1 (en) 2016-12-22
TWI622591B (zh) 2018-05-01
IL255386A0 (en) 2017-12-31

Similar Documents

Publication Publication Date Title
MX2017015837A (es) Procesos e intermediarios para la preparacion de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-piraz ol-1-il]azetidin-3-il}acetonitrilo.
CL2019000942A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
PH12016500676A1 (en) Pyrimidine fgfr4 inhibitors
EP4257613A3 (en) Bispecific checkpoint inhibitor antibodies
MX2015000129A (es) Derivados de pirimidin pirazolilo.
MX2018006148A (es) Inhibidores de cxcr2.
AU2018258581A8 (en) RAF-degrading conjugate compounds
TW201613886A (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
MX2020004255A (es) Compuesto de pirimidina como inhibidor de las janocinasas.
MX2017016041A (es) Metodos para usar activadores de piruvato cinasa.
MX2018008815A (es) Inhibidores de tirosina quinasa de bruton.
MX2018010971A (es) Compuestos y métodos para modular la tirosina cinasa de bruton.
IL250983A0 (en) Triazolo[4, 5-d]pyrimidines as cannabinoid receptor 2 agonists
MX2015013419A (es) Cianoetilpirazolo piridonas aciclicas como inhibidores de janus quinasa.
PH12016501613B1 (en) Pyrazines modulators of gpr6
SG10201908248PA (en) Processes for preparing fluoroketolides
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
HK1232076A1 (zh) 用於取代的 -芐基- 異噁唑- -基甲基 -吡唑- -基 咪唑烷- -二酮的合成的改進方法
EP4045494C0 (en) SYNTHESIS OF 6-METHYL-N1-(4-(PYRIDIN-3-YL)PYRIMIDIN-2-YL)BENZENE-1,3-DIAMINE
MX2015013048A (es) Forma cristalina de un compuesto ansiolitico.
MX2016010268A (es) Pirimidinimidazolaminas como modulares de actividad de cinasa.
TW201612142A (en) Process for preparing 3-chloro-2-vinylphenol
MX2018005376A (es) Derivados de azetidina para formacion de imágenes de tau.
SI3621966T1 (sl) Derivati pirazol(1,5-A)pirimidina kot kinazni JAK inhibitorji
NZ737572A (en) Intermediate compounds for the preparation of bipiperidine-2-one compounds